Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Mediators of Inflammation|February 16, 2018
Distinct Signature of Oxylipid Mediators of Inflammation during Infection and Asymptomatic Colonization by E. coli in the Urinary BladderNandakumar Packiriswamy, Jeff Gandy, Sara N Smith, et al.Journal of Cellular Physiology|October 15, 2010
G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFκB activation in primary macrophages and modulates inflammation in vivo in miceSonika Patial, Shipra Shahi, Yogesh Saini, et al.Leukemia|April 25, 2020
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myelomaNandakumar Packiriswamy, Deepak Upreti, Yumei Zhou, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|November 6, 2023
Oncolytic α-herpesvirus and myeloid-tropic cytomegalovirus cooperatively enhance systemic antitumor responsesHaifei Jiang, Rebecca Nace, Emily Ariail, et al.Biorxiv : the Preprint Server for Biology|December 23, 2022
Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variantsMiguel Á Muñoz-Alía, Rebecca A Nace, Baskar Balakrishnan, et al.Mbio|January 9, 2024
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivityMiguel Á Muñoz-Alía, Rebecca A Nace, Baskar Balakrishnan, et al.Cancer Research Communications|June 22, 2026
Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumorsJaime R Merchan, Manish R Patel, Timothy P Cripe, et al.Mayo Clinic Proceedings|June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles VaccinationStephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.Vaccine|March 14, 2022
Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccineKah-Whye Peng, Timothy Carey, Patrycja Lech, et al.Pageof 3